Blood Substitute Partnering 2009-2014

  • November 2014
  • -
  • Currentpartnering
  • -
  • 150 pages

The Blood Substitutes Partnering 2009-2014 provides understanding and access to the blood substitutes partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of blood substitutes partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors blood substitutes technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 20 links to online copies of actual blood substitutes deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of blood substitutes partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in blood substitutes partnering since 2009, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading blood substitutes deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of blood substitutes partnering deals signed and announced since 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the
research, development and commercialization of blood substitutes technologies and products.

Report scope

Blood Substitutes Partnering 2009-2014 is intended to provide the reader with an in-depth understanding and access to blood substitutes trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in blood substitutes dealmaking in the biopharma industry since 2009
Access to summary headline, upfront, milestone and royalty data
The leading blood substitutes deals by value since 2009


In Blood Substitutes Partnering 2009-2014, the available deals are listed by:

Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Table Of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in blood substitutes partnering

2.1. Introduction
2.2. Blood substitutes partnering over the years
2.3. Big pharma blood substitutes dealmaking activity
2.4. Big biotech blood substitutes dealmaking activity
2.5. Most active blood substitutes dealmakers
2.6. Blood substitutes partnering by deal type
2.7. Blood substitutes partnering industry sector
2.8. Blood substitutes partnering by stage of development
2.9. Blood substitutes partnering by technology type
2.10. Disclosed financial deal terms for blood substitutes
2.10.1 Blood substitutes headline values
2.10.2 Blood substitutes upfront payments
2.10.3 Blood substitutes milestone payments
2.10.4 Blood substitutes royalty rates

Chapter 3 - Leading blood substitutes deals

3.1. Introduction
3.2. Top blood substitutes deals by value

Chapter 4 - Dealmaking directory

4.1. Introduction
4.2. Company A-Z
4.3. By deal type
4.4. By industry sector
4.5. By stage of development
4.6. By technology type

Chapter 5 - Partnering resource center

5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking

Appendices

Appendix 1 - Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form - Reports
Order Form - Subscription Access Products

Table of figures

Figure 1: Blood substitutes partnering since 2009
Figure 2: Big pharma - top 50 - blood substitutes deals 2009 to 2014
Figure 3: Big pharma blood substitutes deal frequency - 2009 to 2014
Figure 4: Big biotech - top 50 - Blood substitutes deals 2009 to 2014
Figure 5: Big biotech blood substitutes deal frequency - 2009 to 2014
Figure 6: Blood substitutes dealmaking activity- 2009 to 2014
Figure 7: Blood substitutes partnering by deal type since 2009
Figure 8: Blood substitutes partnering by industry sector since 2009
Figure 9: Blood substitutes partnering by stage of development since 2009
Figure 10: Blood substitutes partnering by technology type since 2009
Figure 11: Blood substitutes deals with a headline value
Figure 12: Blood substitutes deals with upfront payment values
Figure 13: Blood substitutes deals with milestone payments
Figure 14: Blood substitutes deals with royalty rates, %
Figure 15: Top blood substitutes deals by value since 2009
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Dental Bone Graft Substitutes and other Biomaterials Market (Natural, Ceramic, Composite and Polymer) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

Dental Bone Graft Substitutes and other Biomaterials Market (Natural, Ceramic, Composite and Polymer) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

  • $ 4 795
  • Industry report
  • October 2014
  • by Transparency Market Research

Dental bone graft substitution is a surgical procedure that enables replacing missing tooth. Bone grafts are also used in dental procedures to increase the amount of bone required for supporting dental ...

Global Orthopedic Biomaterials Market 2014-2018

Global Orthopedic Biomaterials Market 2014-2018

  • $ 2 500
  • Industry report
  • September 2014
  • by Infiniti Research Limited

About Orthopedic Biomaterial Orthopedic biomaterial deals with the physical and chemical properties of the material that is implanted into the human body as constituents of devices. The material implanted ...

Global Bioactive Material Market 2014-2018

Global Bioactive Material Market 2014-2018

  • $ 2 500
  • Industry report
  • September 2014
  • by Infiniti Research Limited

About Bioactive Material Bioactive materials are part of the biomaterial family and are increasingly becoming popular due to their ability to react with body fluids and tissues without having a negative ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.